Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …

β2-Agonists are effective bronchodilators due primarily to their ability to relax airway smooth
muscle (ASM). They exert their effects via their binding to the active site of β2-adrenoceptors …

Das vorliegende Dokument ist eine Neufassung und Aktualisierung der Leitlinie zur
Diagnostik und Therapie von Patienten mit COPD, die die bisherige Version aus dem Jahr …

The 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy document
recommends assessment of chronic obstructive pulmonary disease (COPD) using …

While the pharmacological management of chronic obstructive pulmonary disease (COPD)
has evolved from the drugs used to treat asthma, the treatment models are different and the …

Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a
network meta‐analysis - Kew, KM - 2014 | Cochrane Library Skip to Content Cookies Our site …

Despite the passionate debate over the use of β2‐adrenoceptor agonists in the treatment of
airway disorders, these agents are still central in the symptomatic management of asthma …

Background Current guidelines recommend treatment with one or more long-acting
bronchodilators for patients with moderate or more severe chronic obstructive pulmonary …

Background It is unclear whether health related quality of life (HRQL) may have a predictive
value for mortality in idiopathic pulmonary fibrosis (IPF). We investigated the relationship …

Background The long-acting muscarinic antagonist (LAMA) umeclidinium (UMEC) and the
combination of UMEC with the long-acting β 2-agonist (LABA) vilanterol (UMEC/VI) are …